Wellspring Financial Advisors LLC Purchases 4,612 Shares of Merck & Co., Inc. $MRK

Wellspring Financial Advisors LLC boosted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 30.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,780 shares of the company’s stock after buying an additional 4,612 shares during the period. Wellspring Financial Advisors LLC’s holdings in Merck & Co., Inc. were worth $2,082,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Chesapeake Wealth Management boosted its stake in Merck & Co., Inc. by 0.6% during the fourth quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock valued at $1,552,000 after buying an additional 87 shares during the last quarter. Syverson Strege & Co boosted its stake in Merck & Co., Inc. by 2.2% during the fourth quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock valued at $436,000 after buying an additional 90 shares during the last quarter. Westside Investment Management Inc. boosted its stake in Merck & Co., Inc. by 3.1% during the fourth quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock valued at $331,000 after buying an additional 93 shares during the last quarter. Valued Wealth Advisors LLC boosted its stake in Merck & Co., Inc. by 26.9% during the fourth quarter. Valued Wealth Advisors LLC now owns 444 shares of the company’s stock valued at $47,000 after buying an additional 94 shares during the last quarter. Finally, Intrua Financial LLC boosted its stake in Merck & Co., Inc. by 1.1% during the fourth quarter. Intrua Financial LLC now owns 8,604 shares of the company’s stock valued at $906,000 after buying an additional 96 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Trading Down 0.5%

Shares of NYSE MRK opened at $118.99 on Thursday. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The business’s 50 day moving average price is $116.58 and its 200-day moving average price is $113.02. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $125.14. The company has a market cap of $293.89 billion, a price-to-earnings ratio of 33.52, a PEG ratio of 2.69 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the prior year, the business posted $2.22 earnings per share. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, sell-side analysts expect that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is presently 95.77%.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Wells Fargo reiterated its Buy rating on Merck, adding to the recent analyst support around the stock and reinforcing confidence in the company’s long-term outlook. Wells Fargo Keeps Their Buy Rating on Merck & Company (MRK)
• Positive Sentiment: Merck and Gilead reported positive Phase III HIV data for their once-weekly islatravir/lenacapavir regimen, which could expand Merck’s infectious-disease franchise if regulatory filings proceed as planned. Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
• Positive Sentiment: Merck said it is expanding its EU digital traceability efforts and exploring options to help address the emerging Bundibugyo Ebola outbreak, highlighting new commercial and public-health initiatives. Merck Expands EU Traceability Push And Targets Bundibugyo Ebola Response
• Positive Sentiment: Technical coverage noted that MRK has moved back above its 50-day moving average while staying above its 200-day trendline, with Keytruda growth and pipeline progress supporting the investment case. Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
• Neutral Sentiment: Merck was highlighted in research roundups and conference coverage, but these items were mainly recap-oriented and did not introduce a major new catalyst. Top Research Reports for Merck, Southern Company & Lumentum Merck & Co., Inc. (MRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Merck and Gilead also ended a Phase III non-small-cell lung cancer study after it failed to meet its efficacy bar, which may temper enthusiasm around some of Merck’s oncology pipeline efforts. Will HIV Win and Lung Cancer Loss in Trials Recast Merck’s (MRK) Risk Reward Narrative?

Analysts Set New Price Targets

A number of brokerages recently commented on MRK. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Citigroup assumed coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price objective for the company. JPMorgan Chase & Co. raised their price objective on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research note on Monday, April 6th. UBS Group raised their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Finally, Barclays assumed coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They issued an “overweight” rating and a $140.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.